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Not just state-of-the-art. One-of-a-kind.

At UT Graduate School
of Medicine in Knoxville,
we’re conducting medical
research, some of which
cannot be accomplished
anywhere else. Through
collaborations, our
world-class researchers
and faculty physicians
have access to equipment
and treatments that often
mean UT is the ﬁrst to
move breakthroughs from
labs to patient care.

We’re building a healthier world beginning right here
in Tennessee. And that’s work we can all appreciate.

Finding tomorrow’s treatments, today.
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As the region’s only academic medical
center, we are proud to provide the
widest array of comprehensive services
for our patients and their families. Our
focus on patient care is complemented
by focused research to help us learn
more about diseases and to improve
the delivery of care.
In this issue of Frontiers, we highlight
examples of research being conducted
at the University of Tennessee Medical
Center. Our researchers are making
great strides and are learning more and
more about cancer, Alzheimer’s disease,
the effects of anesthesiology, and other
topics in keeping with our strategic
focus. You will see research does not
always take place in a laboratory and is
just as likely to be found at the bedside.
Our patients benefit from the skill and
expertise of health professional who are
constantly asking the question “why”?
True academic medical centers bring
together outstanding patient care,
challenging clinical training, and
stimulating research and we are proud
to provide these advantages for the
patients we serve from throughout
East Tennessee. I hope you enjoy this
issue and the opportunity to learn more
about the importance of research and
how its many shapes and forms impact
our lives and the care we provide for
our patients.
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The Importance of Medical Research

The Importance

of Medical Research

O

ne of the great benefits the
University of Tennessee Medical
Center provides to our community is
serving as a source of new discovery
that leads to improved medical treatment,
even before it’s readily available to
the rest of the world. We take this
responsibility very seriously.
The beginning of the modern era of
medicine was sparked by the idea that
medical treatment of disease should be
based on well-designed research. With
all the diseases known to humankind,
it’s clear that this is a huge undertaking
none-the-less. Everyone deserves
medical treatment based on good
science, not guesswork.
Research processes used today
fall into three major divisions: basic
research (often called bench research),
translational research, and clinical
research. Here is a general overview
of each:

Basic Research is used to make
discoveries in a controlled environment,
frequently in a laboratory setting or on
a computer. It’s where basic understanding
of the medical issue at hand unfolds.

Translation Research takes the
discoveries from the basic research
setting and “translates” them into
methods for treatment or diagnosis of
specific diseases and determines if the
research should progress to the larger
clinical setting.

Clinical Research takes the discoveries
to clinical application. It starts with
very basic interventions, which lead
to larger and more complex research
designs that ultimately define the
standard of treatment.

Throughout the entire process, strict
rules and continuous oversight control
the way research is carried out. All
clinical research must be approved
by the Institutional Review Board,
a committee of experts, whose primary
role is to protect the welfare and safety
of research participants. As the region’s
only academic medical center, the
University of Tennessee Medical Center
and UT Graduate School of Medicine
are proud to make our contribution
to the progress of medical care through
research. In this issue of Frontiers,
we share with you some of what
we’re doing in all three areas—basic,
translational, and clinical research.
Our physicians and researchers
are committed to working together
to bring new and more effective
treatments to the patients we serve.
It is who we are.

Steven R. Ross, DPh, MS

“ I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I
I took the one less traveled by,
And that has made all the difference.”
Robert Frost
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Lessons from the Lab
Vascular Research

How Vascular Research is Benefiting Women’s Health

W

omen develop both cardiovascular
disease and peripheral arterial
occlusive disease at older ages than
men. The difference in this onset,
it was thought, is due to the protective
effect of female estrogen hormones
until menopause. That is why many
researchers and physicians expected
hormone replacement therapy (HRT)
to benefit women in helping to prevent
cardiovascular events. But recent clinical
trials indicate that the protective effect
of HRT works only for women who
start taking the therapy before
they have a cardiovascular
procedure, such as an
endovascular stent. Recent
studies by the Vascular

Research Laboratory at the University
of Tennessee Medical Center confirm
that postmenopausal women who
receive HRT after vascular reconstruction
procedures face a greater risk that these
reconstructions will fail.
Oscar Grandas, MD, an assistant professor
of surgery at UT Graduate School of
Medicine and the scientific director
of the Vascular Research Laboratory,
has taken these clinical findings to
the basic science lab to
answer the fundamental
question of how HRT
affects vascular

functions and causes an altered response
of the vascular wall. The findings suggest
that women who are taking HRT have a
greater chance of developing intimal
hyperplasia, a form of vascular wall
thickening, than women not on the
drug therapy. This is believed to be
because the HRT modifies the balance
of the enzymes that regulate the deposition
of proteins and the movement of cells
within the vascular wall layers, which
causes thickening on the inside structure
of the vessel. When the inside of the
vessel is thickened, it can close off
and lead to stent or bypass graft failure.

Oscar Grandas, MD, reviewing cell
samples in the Vascular Research lab

4

Levels of MMP-2 Activity

The Vascular Research Laboratory at
the University of Tennessee Medical
Center is known as a leader in developing
treatments to enhance patients’ lives.
The research done here takes common
clinical problems to the laboratory
and returns large contributions to the
medical community and its knowledge
base. Scott Stevens, MD, director of
endovascular surgery and a professor
of surgery at UT Graduate School
of Medicine, says, “One of the most

important things about
vascular research is being
able to take what we learn
and apply it clinically to help
our patients at the Heart Lung
Vascular Institute.” With
notable advances and emerging
technologies for the treatment
of vascular problems, patients
in the Knoxville area have the
opportunity to receive some
of the best vascular care
around. “What’s even better,”
says Stevens, “is getting to see
the research come full circle
to help someone and make a
difference in their life.”
Heather Grieve

“ One of the most important things about
vascular research is being able to take what
we learn and apply it clinically to help our
patients at the Heart Lung Vascular Institute.”

H

ormone Replacement Therapy
(HRT) modifies the enzyme balance
that regulates protein deposition and cell
movement within the vascular wall layers.
This protein is called matrix metalloproteinases (MMPs). MMPs allow cells in the
outer layers to move into the inner layer
of the blood vessel, which causes thickening
and eventually narrowing of the blood vessel.
The graph below shows the effect of
hormone exposure on vascular smooth
muscle cells, with the resulting increase
in the activity of the MMP’s protein, which
UT researchers believe play a central role
in the unexpected unfavorable effect of
HRT in women and vascular disease.

MMP-2 Activity
(percent change vs. control)

“This bench study deals with not only
what happens to the vessels as a result
of drug therapy, but also how the timing
of when a woman begins HRT affects
her outcome,”says Grandas.“Understanding
how the cells inside the vascular system
react to hormone exposure will lead
to knowledge of how to better care
for our patients.”

160
*

*

*

120
80
40
0

Control

Estrogen

Progesterone Estrogen +
Progesterone

Scott Stevens, MD

The picture on the left shows a normal
carotid artery, and the one on the right
shows a carotid artery exhibiting intimal
hyperplasia, a form of vascular wall thickening.
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Blocking the Path to Pain

Blocking the Path to Pain,
Clearing the Path to Research in Anesthesiology

C

uriosity. Answering the “what ifs.”
A drive for improvement. These
are the qualities shared by most of
the physicians in the Department of
Anesthesiology who conduct research.
Certainly they do their jobs very well.
They provide the best possible care for
patients from the moment the patients
are admitted for surgery until they leave
the Medical Center; they provide services
for more than 18,000 procedures during
surgeries; and they provide medical
management for many other patients
throughout the University of Tennessee
Medical Center.

But our anesthesiology team doesn’t
stop there. They simply cannot. Their
medical curiosity and high ideals won’t
let them. So they also conduct continual
research in how to improve patient
care and how to advance the science
of anesthesiology beyond current
standards. In our academic medical
center setting, this groundbreaking
research thrives—and many times,
because it is conducted locally, our
patients benefit first.
“I do research simply because I have
clinical and basic science questions
for which I would like answers,” says
Robert Craft, MD, UT Graduate School
of Medicine associate professor and vice
chair of anesthesiology.

6

“I believe academic physicians should
be the ones attempting to answer these
questions, since we have the resources
at this academic medical center and
graduate school of medicine. We also
have the responsibility to educate
resident physicians on the methods of
investigation.”
The anesthesiology research lab
supports the anesthesiology faculty
physicians and resident physicians who
are conducting research on pain and
nausea management, blood clotting,
cardiovascular disease, the effects of
anesthesia, and more.

“ We help the physicians
find answers.”
Roger Carroll, PhD
Director of Anesthesiology
Research
“Our lab provides the bench laboratory
skills and equipment to facilitate clinical
research projects,” says Roger Carroll,
PhD, a professor and the director
of Anesthesiology Research. “We also
advise on the design and execution
of proposed research projects and
assist with the final statistical analysis.
We help the physicians find answers.”
Amanda Johnson

Examples of
Anesthesiology Research
Blood-clotting
Hemorrhage associated with bloodclotting disorders, or coagulopathy, is a
major cause of death and complications
in trauma patients. Russ Langdon, MD,
Roger Carroll, PhD, and their team are
studying whether the rigidity of blood
during blood clotting affects the fatality
rate and how platelets in the blood
during trauma can affect the need
for or the risks of blood transfusion.
Their study could help physicians
in the Emergency Department assess
coagulopathy and other disorders
at an early stage during treatment
of a trauma, and could indicate more
effective interventions.

Cardiovascular Disease
Using data from previous studies on
aspirin resistance, Robert Craft, MD,
Jack Chavez, MD, and other investigators
are testing the correlation of aspirin
resistance in patients with a history of
cardiovascular disease and the formation
in their blood of an agent that
constricts blood vessels. This study
could help physicians more effectively
treat patients who have cardiovascular
disease but also experience aspirin
resistance.

Anesthesia
An upcoming study, headed by Robert
Craft, MD, will use positron emission
tomography (PET) technology to look
at the molecular and anatomical targets
of anesthesia. A better understanding
of the actions of anesthesia can help
anesthesiologists control and increase
the success of its use. This study will
also provide information about the
origin of human consciousness, which
in turn could help explain disturbances
of consciousness such as coma, autism,
and schizophrenia.
Another progressive study on
anesthesia is helping physicians safely
use anesthetic agents during uppergastrointestinal endoscopies and
colonoscopies. Physicians Stephen
Patteson, MD, Jerry Epps, MD, and
others used brain-wave function to
determine the depth of sedation
achieved by using certain anesthetic
agents for endoscopies. They found
that the level of sedation is consistent
with general anesthesia and that for
maximum patient safety, medical
professionals with formal anesthesiology
training should administer the anesthetic
during endoscopies.

(From front) Stephen Patteson, MD;
Robert Craft, MD; Jack Chavez, MD;
and Roger Carroll, PhD, gather in the
Anesthesia Research Facility where they
and others conduct clinical research.
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Research
Collaborations:
Research Collaborations

Focused on the Goal
Economic woes are affecting many areas of life.
From gas and food prices to the costs of mortgage
and college loan repayments, consumers and businesses
are finding ways to ease the pinch. Partnerships with
industry are one solution that allows our academic
medical center to stay focused on the goal—groundbreaking research results that help improve lives.
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A

s nonprofit institutions and
government agencies such as
the National Institutes of Health (NIH)
reduce research funding to respond
to economic conditions, companies
and universities are turning to joint
collaborations to continue important
medical and industrial research.

For-profit companies that make
medicines and medical equipment
are finding it increasingly important
to gain access to the top-notch scientists
at academic medical centers. Likewise,
institutions housing research expertise
are finding that corporate partnerships
can provide financing that allows globally
significant medical research to continue
revealing answers important to us all.
“Partnering with industry allows the
scientific brainpower of our academic
medical center to blend with the business
firepower of industry, a major advantage
to patients seeking the latest treatments
and newest medical equipment,” explains
vascular surgeon Scott Stevens, MD,
a researcher and professor. “You see,
once the Federal Drug Administration
(FDA) approves a new medical device,
the manufacturer will seek out those
institutions known to have a strong
track record in that specialty and can
also adhere to the very stringent guidelines
set by the FDA for the use of the new
device. This is one reason why the
University of Tennessee Medical Center
can provide treatments for people with
vascular disease that are not available
anywhere else in the region.”

The University of Tennessee Graduate
School of Medicine is home to many
such research collaborations, which
inevitably bring cutting-edge treatments
and technologies to the Medical Center.
Researcher Jonathan Wall, PhD, explains
the process in this way: “Companies are
much more likely to establish clinical
trials at institutions that have helped
with the science from the beginning.
First, a company making a compound
or device asks us to use our science to
investigate why and how the product
works. Once that is determined and the
FDA approves the use of the product,
companies are likely to return to the
institution to perform the subsequent
clinical trials. That’s what makes having
an academic medical center in our area
so very important. It gives our community
access to cutting-edge equipment,
treatments, and diagnostic techniques.”
Thanks to research collaborations with
Siemens, the PET/CT scanners at the
University of Tennessee Medical Center
are state of the art. “We absolutely have
one of the best clinical imaging platforms
in the world,” says Wall.

Very high FDA standards and protocols
must be met before any new devices,
equipment, or treatments can be used,
and patients must request and then
agree to their use in treatment.
Brian J. Daley, MD, a professor,
researcher, and surgeon, explains why
companies seek partnerships with the
University of Tennessee Medical Center.
“All our research is rigorously controlled,
government-monitored research.
Companies know we provide a
medically sound setting for a safe,
productive, responsible project.”
Fostering relationships between
the Medical Center and industry can
mean the East Tennessee community
is first in line to access the latest FDAapproved therapeutics. “The Medical
Center is a national leader in the
endovascular field and is known for
the very fine treatments done here,”
says Stevens. “Companies know we
have expertise and processes already
in place that they cannot cost-effectively
pull together quickly, and they contact
us to begin approved treatments here.”
Lea Anne Law

(From left) Researchers John H. Dougherty, MD; David Townsend, PhD;
Jonathan Wall, PhD; Scott Stevens, MD; and Valerie Berthelier, PhD
Fall 2008
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Research Collaborations

Examples of Collaborative Research
Alzheimer’s Vaccine – Patients
from across the country may soon
be traveling to the University of
Tennessee Medical Center to receive the
first monoclonal antibody vaccine that
might reduce the debilitating effects
of Alzheimer’s disease. John Dougherty,
MD leads one of the elite group of
centers worldwide that is evaluating
the latest antibody therapy for the
treatment of Alzheimer’s.

Amyloidosis Diagnosis
and Treatment Response –
UT Graduate School of Medicine
researchers are working with
a company to develop noninvasive
methods to determine whether a
patient has amyloidosis, a condition
that occurs in a significant number
of patients with rheumatoid arthritis.
Using some of the world’s most
sophisticated imaging equipment,
the researchers are helping the world
of medicine understand and diagnose
the disease and monitor patients’
response to therapy.

Aortic Aneurysm: Repair and
Pressure Monitoring – Partnering

Clotting-Agent Safety – David

with Oak Ridge National Laboratory
(ORNL) and CarioMems, a Georgia
Tech start-up company, the University
of Tennessee Medical Center’s
endovascular research team used
the world’s most powerful computing
programs to study images of aneurysms
and determine the rupture risk caused
by pressure in weakened, ballooned
areas in blood vessels. Armed with this
information, Medical Center physician
researchers used pressure-sensor technology designed for military jet engines
to help craft a miniature radio chip that
can be embedded into a vessel during
a stent procedure. In subsequent office
visits, a wandlike device outside the
body can be used to read the vessel
pressure inside the body.

Biodistribution Studies –
A pharmaceutical company, Advion,
has worked over the last 12 months
with UT Graduate School of Medicine
and David Townsend, PhD and Jonathan
Wall, PhD assisting them by tagging
novel compounds with radioactive
molecules and monitoring these with
PET/CT imaging to determine where
the molecules distribute in the body.

Cassada, MD and a team of researchers
from the University of Tennessee
Medical Center’s Department of Surgery
are helping substantiate the safety of a
company’s topical preparation to quickly
clot blood during spinal and vascular
surgery. This same team helped
research a sealant that “glues” vessels
together following bypass grafting
surgeries. The product is now on the
market and used in medical facilities
worldwide.

Huntington’s Studies – In the
UT Graduate School of Medicine
Conformational Diseases and
Therapeutics Research lab, Valerie
Berthelier, PhD is homing in on
Huntington’s disease, a lethal condition
that results from the degeneration
of brain cells. Working with ORNL’s
Neutron Scattering Science division,
she is focusing on identifying molecules
created as the disease progresses, a
study that may result in new therapies.
Lea Anne Law

“ Companies know we
provide a medically sound
setting for a safe, productive,
responsible project.”
Brian J. Daley, MD
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IRB: Ensuring Safe and Ethical Research

Institutional
Review Board

Ensuring Safe
Ethical Research

Gary T. Smith, MD
Chair

Mark E. Anderson, MD

Anjali Arora-Todd,
PharmD

Kenneth Bielak, MD

David Cassada, MD

Martha F. Earl, MSLS

Karl F. Hubner, MD

Francis S. Jones, MD

Stephen Krauss, MD

Kim Currie Mason,
PharmD

Linda Mefford, PhD

Powell Partridge,
Community
Representative

Edwin S. Rogers, PhD

Jean Teague,
Community
Representative

A

ll research studies using human
volunteers must follow stringent
federal regulations that require a review
by an Institutional Review Board (IRB)
before the study is approved. The IRB
Committee, comprised of physicians,
pharmacists, scientists, researchers,
and non-scientific community
representatives, reviews research
protocol to ensure protections are in
place for people volunteering in the
study.
We thank the current and past
members of the IRB at the UT Graduate
School of Medicine who have given
countless hours to ensure patient safety
and promote life-changing research.
Current members include:
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It’s Not Just Brain Science

It’s Not Just Brain Science

John H. Dougherty, MD conducts research on Alzheimer’s disease that may affect 15 million people by 2050.

I

f asked to explain the word
“neuroscience,” most of us would
likely use the words “brain science”
somewhere in our simple description.
However, as you might guess, this
branch of the life sciences is much
more complex, concerning itself with
the anatomy, physiology, biochemistry,

12

or molecular biology of the entire
nervous system, including the brain,
spinal cord, and network of sensory
cells throughout the body.
Scientists are fascinated by neuroscience
research, in particular studies focused
on several well-known diseases—

Alzheimer’s, Huntington’s, Parkinson’s.
Each of these diseases can significantly
impact quality of life, and researchers
at the University of Tennessee Medical
Center’s Cole Neuroscience Center and UT
Graduate School of Medicine are making
discoveries that can detect, and
sometimes delay, their onset.

Research in fighting these crippling
diseases starts at the smallest level:
the molecule. A research team led by
George Kabalka, PhD, professor, Robert
H. Cole Chair in Neuroscience, and
director, Basic Research,
Department of Radiology,
UT Graduate School of
Medicine, builds molecules that have never
existed before to target
the causes of these
diseases.

amyloid diseases and in the fight
against Parkinson’s and Alzheimer’s.

Patients with Parkinson’s disease have
a decrease in the activity of neuroreceptors
in the brain, leaving
victims incapable of
initiating or controlling
movement. Kabalka’s team
has created isotopically
labeled neuroreceptor
molecules that travel to
the neuroreceptors, and
using PET imaging, can
show physicians the
“We work with physicians
George Kabalka, PhD
activity—or lack of
and biologists to discover
activity—in the brain.
molecules that naturally
target organs or diseases,” says Kabalka,
Similar research with promising results
“and with that knowledge, we can
is being conducted for Alzheimer’s.
envision how to put a short-lived
radioisotope into the molecule, which
Alzheimer’s disease is a condition that
travels straight to the tumor or diseased
cripples the ability of millions of older
area within the body.”
Americans to think and manage their
lives. However, says John Dougherty,
That’s when imaging, namely positron
MD, director of the Cole Neuroscience
emission tomography (PET), becomes
Center, because of the soaring numbers
invaluable.
of people with the disease, the search
for a cure for Alzheimer’s promises
“Using modern medical imaging,
breakthroughs in patient care across
physicians can evaluate the activity
the board.
level of the disease, which enables
them to both diagnose and monitor
“It’s a disease that has great impact,
the disease prior to, during and after
because people live for a long time
treatment,” says Kabalka. “We’ve already
with it and they slowly get worse,”
successfully used this technology in
says Dougherty. “Because the
patients, and with additional medical
population of people 85 and older
funding, our research can continue
is going to grow tremendously, by
to expand.”
the year 2050 there will be 14
or 15 million people with
The molecules created in Kabalka’s labs
Alzheimer’s disease.”
are used for research in oncology and

This is why researchers at the Cole
Neuroscience Center, in the UT
Graduate School of Medicine Human
Immunology and Cancer Program
run by Alan Solomon, MD, in the UT
Graduate School of Medicine Molecular
Imaging and Translational Research
Program headed by David Townsend,
PhD, and in Kalbalka’s group, are leading
several research initiatives focused on
Alzheimer’s and other neurological
disorders.
One of the largest research efforts in
neuroscience is just getting under way.
A $300 million study of the use of
monoclonal antibodies, disease-fighting
agents reproduced from a single cell,

Fall 2008
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It’s Not Just Brain Science
to battle Alzheimer’s disease is enrolling
patients at some 100 sites across the
United States, including the University
of Tennessee Medical Center. Initially
approved for the treatment of about
16 patients in the study, the Medical
Center could eventually contribute data
on up to 50 patients, Dougherty says.
Researchers believe Alzheimer’s disease
affects patients’ brains through clusters
of protein fragments, known as amyloid.
It is believed these clusters accumulate
and attract other proteins to form
abnormal plaques in brain tissue,

Exercise Your Brain
It is always good to exercise your
brain. Performing daily brain tests
will help keep your brain active and
healthy. Try this brain test now:
1. Say the days of the week backwards,
then in alphabetical order.
2. Say the months of the year in alphabetical
order. Easy? well, why don’t you try doing
so backwards, in reverse alphabetical order.

which cause degeneration. Monoclonal
antibodies engineered to neutralize
amyloid have been proved to work
in laboratory studies.
“In laboratory models,” says Dougherty,
“the monoclonal antibody produces
a spectacular response. It sucks the
amyloid out of the brain and improves
memory.” Early clinical tests were
so promising that the FDA approved
moving forward with the multi-center
trial of the monoclonal antibody.
Solomon’s group at the Graduate School
of Medicine has been researching
amyloid-related diseases—including
Alzheimer’s, Parkinson’s, Lou Gehrig’s,
Huntington’s, type 2 diabetes, amyloidosis,
and others—for decades. One recent
study reported a link between foie gras
prepared from goose or duck liver and
the type of amyloid found in arthritis
or tuberculosis; another identified a
structurally unique protein in a rare

Intelligence, Judgement,
and Behavior
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Dougherty says success in the treatment
of other neurological disorders, such as
Parkinson’s disease, could be models for
the fight against Alzheimer’s. “The new
mantra in Alzheimer’s disease is prevention
and delay,” he says. “If you can put off
the symptoms of Alzheimer’s disease three
to five years, you can decrease the number
of people with the disease by half.”

John Yates

4. Name two objects for
every letter in your
complete name. Work
up to five objects, trying
to use different items
each time.

Harriet Vines, PhD

Work by Brian O’Nuallain, PhD, a
member of Solomon’s team, may also
be useful in delaying Alzheimer’s disease.
He discovered an intravenous antibody
product that is used as antibodyreplacement therapy for patients with
autoimmune disease contains naturally
occurring human antibodies that bind
to A-beta, the protein fragment believed
to be the chief culprit in Alzheimer’s
disease. Antibodies are proteins that
attach to foreign proteins and remove
or neutralize them.

And prevention and delay of these
diseases ultimately improves your
quality of life—for life.

3. Find the sum of your date of
birth, mm/dd/yyyy. Want more
exercise? Do the same with
friends’ and relatives’
date of birth.

5. Wherever you are, look around and
within two minutes, try to find 5 red
things that will fit in your pocket, and
5 blue objects that are too big to fit.

dental tumor that may assist in targeting
therapy for other cancers such as breast,
lung, and gastrointestinal.

Illustration of the areas of
the cerebral cortex commonly
affected by Alzheimer’s disease.

Language
Memory

Donor Profile

Donor Profile:

The Cole Foundation

A

s an organization that relies heavily
on private donations to stay on the
cutting edge of technology and to fund
innovative treatments and programs,
the University of Tennessee Medical
Center has been fortunate to have
a long-time friend and financial
supporter in the Robert H. and
Monica M. Cole Foundation.
Following a diagnosis of Parkinson’s
disease in 1967, Bob Cole was moved
to find a way to support research and
treatment methods for others with the
same illness. The result was an initial

$1 million endowment, made in 1968,
which established the Cole Foundation.
Support of the University of Tennessee
Medical Center has continued over
the years.
In 1994 a grant was provided to
enable the Graduate School of Medicine
to create the Cole Foundation Endowed
Chair of Neuroscience. Its first professor,
George W. Kabalka, PhD, is widely
recognized as a leader in neuroscience
research and whose discoveries resonate
far beyond the halls of the Medical Center.
The Medical Center’s
Brain and Spine Institute,
too, has benefited
tremendously from
the Cole Foundation’s
support, receiving a
generous grant that
led to the creation
of the Cole Neuroscience
Center. The center is
dedicated to helping
those who suffer from
neurological conditions
such as Alzheimer’s,
epilepsy, Parkinson’s,
and multiple sclerosis.

The Cole Foundation has also actively
supported the University of Tennessee
Medical Center Pastoral Care Program,
which focuses on the physical, spiritual,
and emotional aspects of healing for
both patients and their loved ones.
Adding to the list, the Medical
Explorations program, a mentoring
program for young people interested
in healthcare careers, has received
financial support from the foundation.
For 40 years the Cole Foundation
has remained committed to its original
mission of helping others. The Cole
family continues to be active in the
foundation’s management, and several
of its members sit on the board of
directors, providing generous guidance
to the many programs the foundation
supports. Through the continued
support of the Cole family and the Cole
Foundation, researchers and physicians
at the University of Tennessee Medical
Center and UT Graduate School of
Medicine have access to resources that
inspire discoveries and offer so many
new hope and improved quality of life.
Rachel Greene

Mrs. Monica M. Cole with a portrait of her husband, Robert H. Cole.
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Translational Research Benefits Cancer Patients
“
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T

here’s an innovative concept
in medicine known as translational
research,” says Eric Carlson, DMD, MD,
chairman of the Department of Oral
and Maxillofacial Surgery at the University
of Tennessee Medical Center. “Translational
research involves taking a basic science
concept and converting it to the clinical

level, so something that’s discovered in
the lab can translate into a benefit
for patient care.”
In the field of cancer research, clinicians
at the University of Tennessee Medical
Center, such as Carlson, are teaming
up with colleagues in the basic sciences.
And the results have been impressive.

CT

Carlson says he works with
“a world-class team in molecular
imaging and translational research.
When I came here six years ago,
one of my expressed intentions
was to collaborate with as many
basic science researchers in the
Medical Center as possible. I’ll
develop a clinical idea, and they
put it into scientific language. This
represents a perfect collaboration
between a clinician and a researcher.
That’s one of the elements of my
career that I thoroughly enjoy.”
These translational collaborations
have generated several fruitful lines
of research. With physicist David
Townsend, PhD, director of the UT
Molecular Imaging and Translational
Research Program, Carlson is studying
the use of PET/CT imaging in staging
oral and head-and-neck cancers.
In cancers of the oral cavity, metastasis
usually occurs first in the lymph nodes
on the side of the neck closest to
the primary cancer. The dilemma
for physicians, says Carlson, is that
in many of these cases, the cancer
metastasizes to the nodes in the neck
that can’t be detected by clinical exams
or imaging studies.
PET/CT, a pairing of positron
emission tomography (PET) and
computed tomography (CT), has
rapidly become the imaging tool of

PET

PET/CT

PET, CT, and PET/CT images show metastatic nodes from a primary tumor in the right tonsil.

choice in such cases. It was devised
10 years ago by Townsend and Ron
Nutt, PhD, then CEO of CPS
Innovations, a PET company based
in Knoxville that is now part of
Siemens Molecular Imaging.
The combination of CT, which images
the anatomy and location of suspicious
growths or enlarged lymph nodes, and
PET, which identifies abnormal or
suspicious metabolic activity that
can be characteristic of cancer, helps
clinicians identify and localize cancerous
tissues. Carlson and other clinicians

rely on PET/CT imaging because of
the images’ quality and their usefulness
to clinicians in determining the best
way to fight cancer.
This continued research increases the
likelihood that the PET/CT device and
molecular markers will continue to be
improved. Because surgeons routinely
remove lymph nodes in the neck, the
ongoing study allows comparison
of the lymph nodes removed during
surgery with the preoperative images
as a check on those images’ accuracy.
While PET/CT is important for effective

David W.Townsend, PhD, and Eric Carlson, DMD, MD
Fall 2008
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diagnosis and treatment (“I’m at the
point where I don’t feel comfortable
treating a patient with head and neck
cancer without PET/CT,” Carlson says),
recent research led by Carlson, Townsend,
and co-workers found that PET/CT
alone detected only about 30% of
metastases in those patients. These data
reveal an opportunity to improve the

PET/CT procedure—one that Carlson
and Townsend are actively pursuing
in their research.
Carlson is also collaborating in other
translational research endeavors,
including work with David Gerard,
PhD, in studying the connections
between the genetic makeup of specific

cancer cells and the way they behave
biologically. “The underlying fact,”
says Carlson, “is that cancer is a
genetic disease and the genome creates
a certain behavior.” Using a procedure
called complimentary DNA (or cDNA)
microarray analysis, he says, “we’re
going to take the last 100 or 200
cancers I’ve removed and examine the
genetics of those cancers. Dr. Gerard
will try to predict the biologic behavior,
which I will know (the biologic behavior)
based on the follow-up of these patients.
Results of this study may lead to
examining the genome of a cancer at
the time of the initial biopsy, resulting
in the ability to predict the behavior of
that cancer. Therapy may be adjusted
accordingly in a proactive fashion.”

Wahid Hanna, MD
Eric Carlson, DMD, MD,
(third from left) with the
surgical team.
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Townsend has partnered with other clinicians too, including
recent work with Wahid Hanna, MD, chief of the Medical
Center’s oncology division, on the use of PET/CT to assess
response to chemotherapy as early as possible in patients
with non-small-cell lung cancer.
“Traditionally,” says Hanna, “we give three cycles of
chemotherapy—the cycles would each be about three
weeks long. Then we would wait two weeks and evaluate
the response. Unfortunately, if we do that and we discover
the patient has not responded, we’ve wasted valuable time.”
If the patient doesn’t respond to one chemotherapy regimen,
another may be tried, but as the cancer progresses the
patient’s condition may weaken. “Sometimes it’s a race
between us and the cancer,” Hanna says.
In a study of 18 patients, Hanna reports that PET/CT imaging
was able to accurately predict responses to chemotherapy
as early as just three weeks into treatment. He’s now testing
a larger group of 50 patients to confirm those results. If the
results hold, PET/CT might be used to fine-tune chemotherapy
early in the treatment.

“ There are now approximately 15 million
people living in this country who have
survived cancer.They’re survivors because
of the research that occurred over the
past 50 years.”
John L. Bell, MD
Because this kind of research improves patient outcomes,
it has long been part of what the Medical Center is all about.
“We do the most research of any medical facility in town,”
says Barbara Munsey, the center’s clinical trials manager.
“In an academic medical center like ours, it’s a major part
of our mission. It’s understood that we’re doing research
for the greater good.”
“Basic science, clinical and translational research allows us
to identify ways to diagnose cancers earlier and to treat people
with less toxicity and fewer side effects,” says John L. Bell, MD,
director of the University of Tennessee Medical Center’s
Cancer Institute. “There are now approximately 15 million
people living in this country who have survived cancer.
They’re survivors because of the research that occurred
over the past 50 years.”
John Yates

New Discovery

T

he discovery of a structurally unique protein
in jaw tumors by scientists at the University
of Tennessee Graduate School of Medicine’s
Human Immunology and Cancer Program could
have important implications for the diagnosis
and treatment of certain diseases.
An article published in the May/June 2008 issue
of Molecular Medicine by a team headed by Alan
Solomon, MD, reported the discovery of odontogenic
ameloblast-associated protein (ODAM). The team
found that amyloid associated
with a rare jaw tumor
was composed of ODAM
fragments, the first evidence
of expression of the unusual
protein.
Subsequently the team
made antibodies to ODAM,
as well as recombinant
ODAM, and serendipitously
found the molecule was
expressed not only in jaw
tumors but also by other
epithelial cancers, including
breast, gastrointestinal, and
lung. Patients with these
malignancies were also
found to have significant
titers of anti-ODAM
antibodies in their blood.

Alan Solomon, MD

ODAM Protein

Follow-up efforts, says
Daniel Kestler, PhD, a lead
researcher in the study, “are
directed toward delineating
why ODAM is expressed in
Daniel Kestler, PhD
these cancers, as well as the
function of this protein, its
role in tumorigenesis, and
especially whether it can serve
as a novel tumor biomarker.”

Fall 2008

19

Out of the Lab

Out of the Lab

Pharmacists and Nurses Making
Discoveries Every Day

T

he University of Tennessee Medical
Center has long been known for its
commitment to advancing the science
of medicine. It’s not just part of our
vision, it’s part of our culture. From
nurses to pharmacists, medical professionals who directly care for patients
are actively involved in research aimed
at providing better treatments for our
patients. But this research doesn’t take
place in a laboratory with test tubes
and microscopes. It takes place at the
bedside, and new discoveries are made
each day.
An excellent example of this bedside
approach to research involves the
Department of Pharmacy, where
staff members often look for ways
to improve patient care through
investigational, scientific methods.
In many medical settings, patient
falls are the most common causes
of injuries. Patients sometimes try
to leave their bed unassisted when
they are unable and become injured
as the result of a fall.
Oftentimes, the patients are elderly,
but some pharmacists noticed a
number of falls involving patients
younger than 65. A great deal of
national research linked medication
to falls in elderly populations; however,
none existed for those 65 years of age
and younger. Therefore, a team of
pharmacists at the Medical Center
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decided to study the link between
medications and falls for this younger
population. They found that patients
who fell were taking more medications
than those who didn’t fall and identified two types of medications:
benzodiazepines and anticonvulsants.
The medications caused an increase in
the risk for falls. Because of this study,
caregivers now have another means
of identifying those patients who are
at a greater risk for falling. This, in
turn, provides better care.
The pharmacy department has also
been working on evaluating standards
related to the medication distribution
system. Many hospitals use automated
systems to provide safe, accurate and
efficient medication distribution on
each unit. The systems, however, need
some improvements to ensure safe
transfer of medications and information
when patients are moved from one area
of the hospital to another. At the
University of Tennessee Medical Center,
a patient-specific management software,
never before used in the country, was
tested and shown to enhance patient
safety and medication efficiencies.
“The great thing about an academic
medical center like the University of
Tennessee Medical Center is that
employees feel they can take part in
improving the standard of care applied
throughout the country,” says Director
of Pharmacy, Kim Mason.

The pharmacy department isn’t the only
area where employees are researching
ways to improve patient care. Other
departments like the Neonatal Intensive
Care Unit are making improvements,
right at the bedside.
In the Neonatal Intensive Care
Unit, a study is underway to evaluate
different types of phototherapy devices.
Phototherapy is commonly used
in infants to help the body process
bilirubin, which causes jaundice.
The Medical Center uses three
types of phototherapy devices, but
the medical community as a whole
has not conducted any research to
evaluate the effectiveness of one type
of light over another.

A newborn undergoes one of the
phototherapy treatments in the
Neonatal Intensive Care Unit
behind the research performed at
the Medical Center is still the same.
It is… and always will be… the desire
to improve our patients’ standard of
care and quality of life.

Heather Grieve

As part of the research, patients
consenting to the study are monitored
to find out which phototherapy devices
are the most effective and have the
fewest side-effects. It is expected that
this much-needed study will lead to
more effective ways of treating babies
with high bilirubin levels. Results of
this study will soon be published so
healthcare providers around the world
can benefit from the work being done
here at the University of Tennessee
Medical Center.
In each of these examples, it is clear
that research isn’t necessarily carried
out in a laboratory. It can be performed
in a variety of ways, but regardless of
where it takes place, the driving force
Fall 2008
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In Print:

P

Researchers Share
Scientific Findings

atient care at the University of Tennessee Medical Center
takes place in Knoxville, but the healthcare expertise of our
physicians and scientists spans the globe. Through peer-reviewed
scientific publications, UT Graduate School of Medicine experts
help treat patients and shape ongoing research across the world.

Diabetes Technology and Therapeutics
February 2008
Lorraine Wallace, Amy Keenum, Steven Roskos,
Richelle Koopman, Kristie Young
“Blood Glucose Monitor Quick Reference Guides:
Are They Suitable for Patients?”

Health Place October 24, 2007
Lorraine Wallace, Jennifer Devoe, Ian Bennett,
Steven Roskos, George Fryer Jr.
“Perceptions of Healthcare Providers’ Communication
Skills: Do They Differ Between Urban and
Non-Urban Residents?”

Journal of General Internal Medicine
November 2007

Publications in 2007-08 that focused on our primary clinical areas include

Lorraine Wallace, Jennifer Devoe, Edwin Rogers,
Maricarmen Malagon-Rogers, George Fryer Jr.
“The Medical Dialogue: Disentangling Differences Between
Hispanic and Non-Hispanic Whites”

Brain/Spine/Neuroscience

Journal of Biological Chemistry
August 1, 2007

Journal of Lower Genital Tract Disease
October 2007

Amyloid: The Journal of Protein
Folding Disorders 2008

Romaine Fernando, James Foster, Amber Bible,
Anders Ström, Richard Pestell, Mahadev Rao, Arnold
Saxton, Seung Joon Baek, Kiyoshi Yamaguchi, Robert
Donnell, Maria Cekanova, Jay Wimalasena
“Breast Cancer Cell Proliferation Is Inhibited by BAD:
Regulation of Cyclin D1”

Charles Murphy, Daniel Kestler, James Foster,
Shuching Wang, Sallie Macy, Stephen Kennel, Eric
Carlson, John Hudson, Deborah Weiss, Alan Solomon
“Odontogenic Ameloblast-Associated Protein Nature of
the Amyloid Found in Calcifying Epithelial Odontogenic
Tumors and Unerupted Tooth Follicles”

Biochemistry January 9, 2007
Ronald Wetzel, Shankaramma Shivaprasad,
Angela Williams
“Plasticity of Amyloid Fibrils”

Biochemistry February 6, 2007
Brian O’Nuallain, Anton Allen, Stephen Kennel,
Deborah Weiss, Alan Solomon, Jonathan Wall
“Localization of a Conformational Epitope Common to
Non-Native and Fibrillar Immunoglobulin Light Chains”

Biochemistry November 13, 2007
Brian O’Nuallain, Amy Allen, Demet Ataman,
Deborah Weiss, Alan Solomon, Jonathan Wall
“Phage Display and Peptide Mapping of an Immunoglobulin
Light Chain Fibril-Related Conformational Epitope”

Brain Pathology April 2007
Mahlon Johnson, Charles Stevenson, Reid
Thompson, James Atkinson, Phillip Boyer
“December 2006: 31-Year-Old Woman With Hemiparesis”

Proceedings of the National Academy of
Sciences of the United States of America
June 1, 2007
Alan Solomon, Tina Richey, Charles Murphy,
Deborah Weiss, Jonathan Wall, Gunilla Westermark,
Per Westermark
“Amyloidogenic Potential of Foie Gras”

Cancer
Acta Cytologica 2007
Lisa Duncan, Sanjivini Jacob, Steven Atkinson
“Fine Needle Aspiration Cytologic Findings of
Micropapillary Carcinoma in the Lung: A Case Report”

Cancer Cytopathology February 25, 2008
Lisa Duncan, Sanjivini Jacob, Elizabeth Hubbard
“Evaluation of p16(INK4a) as a Diagnostic Tool in the
Triage of Pap Smears Demonstrating Atypical Squamous
Cells of Undetermined Significance”
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Journal of Oral and Maxillofacial
Surgeons 2007
J. Michael McCoy and Eric Carlson
“Surgical Management of Odontogenic Tumors”

Journal of Oral and Maxillofacial Surgery
September 2007
N. Frazil Erdem, Eric Carlson, David Gerard,
Albert Ichiki
“Characterization of 3 Oral Squamous Cell Carcinoma
Cell Lines With Different Invasion
and/or Metastatic Potentials”

Journal of Oral and Maxillofacial Surgery
May 2008
N. Fazil Erdem, Eric Carlson, David Gerard
“Characterization of Gene Expression Profiles of
3 Different Human Oral Squamous Cell Carcinoma Cell
Lines with Different Invasion and Metastatic Capacities”

Journal of Psychosocial Oncology 2008
Derek Hopko, John Bell, Maria Armento,
Sarah Robertson, Melissa Hunt, Nicole Wolf,
Christine Mullane
“The Phenomenology and Screening of Clinical
Depression in Cancer Patients”

Molecular Medicine April 20, 2008
Daniel Kestler, James Foster, Sallie Macy, Charles
Murphy, Deborah Weiss, Alan Solomon
“Expression of Odontogenic Ameloblast-Associated Protein
(ODAM) in Dental and Other Epithelial Neoplasms”

Health Literacy: Patient and
Physician Communications
American Journal of Health-System Pharmacy
January 1, 2008
Steven Roskos, Lorraine Wallace, Barry Weiss
“Readability of Consumer Medication Information for
Intranasal Corticosteroid Inhalers”

Kimberly Fortner, Nikki Zite, Lorraine Wallace
“In My Own Words: Misunderstanding of Pap Smears
and Colposcopy Among Appalachian Women”

Journal of Opioid Management
November-December 2007
Lorraine Wallace, Amy Keenum, Steven Roskos
“Comprehensibility and Readability of Patient
Self-Administered Opioid Assessment Screening Tools”

Journal of Pain March 21, 2007
Steven Roskos, Amy Keenum, Lindsay Newman,
Lorraine Wallace
“Literacy Demands and Formatting Characteristics
of Opioid Contracts in Chronic Nonmalignant Pain
Management”

Journal of Pain June 12, 2007
Lorraine Wallace, Amy Keenum, Steven Roskos,
Kelly McDaniel
“Development and Validation of a Low-Literacy
Opioid Contract”

Journal of Surgical Research June 15, 2007
Lorraine Wallace, David Cassada, Edwin Rogers,
Michael Freeman, Oscar Grandas, Scott Stevens,
Mitchell Goldman
“Can Screening Items Identify Surgery Patients at Risk
of Limited Health Literacy?”

Patient and Education Counseling
January 4, 2008
Lorraine Wallace, Amy Keenum, Steven Roskos,
Gregory Blake, Strant Colwell, Barry Weiss
“Suitability and Readability of Consumer
Medical Information Accompanying Prescription
Medication Samples”

Heart/Lung/Vascular
British Medical Journal Publishing
Group 2007
Jose Aycinena and Brian Daley
“Acute Pancreatitis”

Circulation 2007
Bret Rogers
“Dyssynchrony Transthoracic Echocardiogram as a
Predictor of Response to Cardiac Resynchronization”

Journal of Cardiothoracic Surgery
January 24, 2008

Journal of Oral and Maxillofacial Surgery
December 2007

Jeffrey Everett, Harold Burkhart
“Coronary Artery Aneurysm: Case Report”

Claude Nahmias, Eric Carlson, Lisa Duncan, Todd
Blodgett, Jason Kennedy, Misty Long,
Chris Carr, Karl Hubner, David Townsend
“Positron Emission Tomography/Computerized Tomography
(PET/CT) Scanning for Preoperative Staging of Patients
With Oral/Head and Neck Cancer”

Journal of Controlled Release April 2, 2007
Vladimir Shuvaeva, Melpo Christofidou-Solomidoub,
Arnaud Scherpereela, Eric Simonef, Evguenia Arguirib,
Samira Tlibaa, Jeremy Picka, Stephen Kennel, Steven
Albeldab, Vladimir Muzykantov
“Factors Modulating the Delivery and Effect of
Enzymatic Cargo Conjugated With Antibodies Targeted
to the Pulmonary Endothelium” Michael Diener, John
Alford, Stephen Kennel, Saed Mirzadeh

Journal of Urology November 2007
Wesley White, Frederick Klein, Judson Gash,
W. Bedford Waters
“Prospective Radiographic Followup After En Bloc
Ligation of the Renal Hilum”

Springer 2008
Nikki Zite
“Gynecology for the Primary Care Physician”

Urology August 17, 2007
M. Eric Brewer, Wesley White, Frederick Klein,
Leslie Klein, W. Bedford Waters
“Validity of Pelvic Pain, Urgency, and Frequency
Questionnaire in Patients With Interstitial
Cystitis/Painful Bladder Syndrome”

Additional research was
highlighted in the following
publications:

Journal of Surgical Education
May-June 2007

Molecular Imaging and Biology
March-April 2007

Michael Lebow, David Cassada, Michael Freeman,
Oscar Grandas, Scott Stevens, Mitchell Goldman
“Preemptive Distal Revascularization-Interval Ligation to
Prevent Ischemic Steal After Hemodialysis Access
Surgery”

Joseph Thie, Karl Hubner, Francis Isidoro, Gary Smith
“A Weight Index for the Standardized Uptake Value in 2Deoxy-2-[F-18]Fluoro-D-Glucose-Positron Emission
Tomography”

Min-Liang Yao, Scott Borella, Travis Quick, George
Kabalka
“Boron Trihalide Mediated Haloallylation of Aryl
Aldehydes: Reaction and Mechanistic Insight”

Pediatric Radiology August 2007

Journal of Vascular Surgery August 1, 2007

Disease-a-Month 2007

Daniel Kirzeder and J. Herman Kan
“Mesenteric Lymphatic Malformation”

Bruce Ludwig and Angeline Lazarus
“Musculoskeletal Tuberculosis”

Physics in Medicine and Biology
February 21, 2008

Ionic Liquids in Organic Synthesis 2007

Michael Lebow, David Cassada, Oscar Grandas, Scott
Stevens, Mitchell Goldman, Michael Freeman
“Acute Pancreatitis as a Complication of Percutaneous
Mechanical Thrombectomy”

Radiation Protection Dosimetry
June 18, 2007

David Townsend
“Multimodality Imaging of Structure and Function”

Tina Dudney, Trent Nichols, Laurence Miller,
George Kabalka
“Microdosimetric Study for Interpretation of Outcomes
From Boron Neutron Capture Therapy Clinical Trials”

Radiology February 2007

Vascular and Endovascular Surgery
August-September 2007

David Townsend
“Positron Emission Tomography/Computed Tomography”

Jacob Barbee, Scott Stevens, Thomas Gaines,
Judson Gash
“Endovascular Repair of Cervical Aortic Arch Aneurysm”

Journal of Vascular and Interventional
Radiology 2007

Vascular and Endovascular Surgery December
2007-January 2008
Daniel Sutphin, Scott Stevens, Daniel Kirzeder,
Judson Gash
“Acute Thrombosis of a Mesenteric Artery Drug-Eluting
Stent Following Clopidogrel Cessation”

Imaging
Journal of the American Chemical Society
April 25, 2007
Michael Diener, John Alford, Stephen Kennel,
Saed Mirzadeh
“(212)Pb@C(60) and Its Water-Soluble Derivatives:
Synthesis, Stability, and Suitability for
Radioimmunotherapy”

Journal of Endourology November 2007

Todd Blodgett, Carolyn Meltzer, David Townsend
“PET/CT: Form and Function”

Seminars in Nuclear Medicine May 2008

Justin Caughron
“Catheter-Directed Thrombolysis and Mechanical
Thrombectomy of a Thrombosed Persistent Sciatic Vein in
a Patient With Klippel-Trenaunay Syndrome”

Dalton Transactions February 14, 2008

George Kabalka, Gang Dong, Bollu Venkataiah
“Organic Synthesis in Ionic Liquids Utilizing
Organometallic Reagents”

Journal of Biological Chemistry
September 14, 2007
Zhibo An, Hong Wang, Ping Song, Miao Zhang,
Xuemei Geng, Ming-Hui Zou
“Nicotine-Induced Activation of AMP-Activated Protein
Kinase Inhibits Fatty Acid Synthase in 3T3L1 Adipocytes:
A Role for Oxidant Stress”

Journal of Homeland Security May 13, 2008
F. Matthew Mihelic, M. David Stockton,
Stephen Cole, Gregory Blake
“The Changing Role of Physicians in Disaster
Management and Hospital Incident Command”

Journal of Organic Chemistry April 4, 2008

Women’s Health
and Pediatrics
American Journal of Reproductive
Immunology January 2008
Antonin Bukovsky and Michael Caudle
“Immune Physiology of the Mammalian Ovary–A Review”

Journal of Pediatric Surgery January 2008
Sabina Siddiqui, Scott Newbrough, Daniel Alterman,
Alan Anderson, Alfred Kennedy Jr.
“Efficacy of Laparoscopic Cholecystectomy in the
Pediatric Population”

Journal of Perinatology February 2008

Wesley White, Nikki Zite, Judson Gash, W. Bedford
Waters, Wayne Thompson, Frederick Klein
“Low-Dose Computed Tomography for the Evaluation of
Flank Pain in the Pregnant Population”

Mark Gaylord, Maureen Greer, John Botti
“Improving Perinatal Health: A Novel Approach to
Improve Community and Adult Health”

Journal of Nuclear Medicine May 2007

Journal of Perinatology September 2007

Claude Nahmias, Wahid Hanna, Lindi Wahl,
Misty Long, Karl Hubner, David Townsend
“Time Course of Early Response to Chemotherapy in
Non-Small Cell Lung Cancer Patients With 18F-FDG
PET/CT”

Mark Anderson, Terry Longhofer,
Ward Phillips, David McRay
“Passive Cooling to Initiate Hypothermia for Transported
Encephalopathic Newborns”

Progress in Molecund Subcellular
Biology 2007

George Kabalka, Min-Liang Yao, Scott Borella,
Zhongzhi Wu, Yu-Hong Ju, Travis Quick
“Boron Trihalide Mediated Alkyne-Aldehyde Coupling
Reactions: A Mechanistic Investigation”

Journal of Surgical Research January 2007
Robert Gillis, Brian Daley, Blaine Enderson, Daniel
Kestler, Michael Karlstad
“Regulation of Apoptosis in Eicosapentaenoic
Acid-Treated HL-60 Cells”

The Journal of Urology January 2008
Wesley White, Cindy Dobmeyer-Dittrich, Frederick
Klein, Lorraine Wallace
“Sacral Nerve Stimulation for Treatment of Refractory
Urinary Retention: Long-Term Efficacy
and Durability”

Urology June 2007
Michael Brewer, Robert Wilmoth, Blaine Enderson,
Brian Daley
“Prospective Comparison of Microscopic and Gross
Hematuria as Predictors of Bladder Injury in
Blunt Trauma”

Kandi Hodges

Antonin Bukovsky
“Cell Commitment by Asymmetric Division
and Immune System Involvement”
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Course Calendar
UT CME

If you are a physician, researcher, allied healthcare professional, or
faculty member seeking continuing medical education, you may be interested
in these upcoming activities offered by the UT Graduate School of Medicine.

October 3-4

Fall 2008

Heart, Lung, Vascular: Update
for Primary Care Providers
UT Conference Center, Knoxville

Regardless of age or race, cardiovascular and
pulmonary diseases affect a large number of
Tennesseans. This year’s conference will explore
symptomatic aortic stenosis, abdominal aortic
aneurysm, hypertension, peripheral vascular
disease, and lipid-lowering strategies in at-risk
patients based on specifics for race and gender groups.

November 8

New strategies and treatment options are coming
to light every day. “Heart, Lung, Vascular: Update
for Primary Care Providers” is a course that
can help physicians, nurses, and allied health
professionals tackle this looming health issue
by providing the latest information and tools
from regional experts.

Dr. R. Ben Alley Endowed
Lecture Series
Morrison’s Conference Center,
University of Tennessee Medical Center
The featured speaker is Leon Assael, DMD, professor and chair
of the Department of Oral and Maxillofacial Surgery at the
Oregon Health and Science University School of Dentistry.
A graduate of Columbia, Harvard, and Vanderbilt universities,
Assael will share his knowledge of facial injuries, facial pain, and
maxillofacial nerve injuries—his primary clinical interest—with
lecture participants in November. The biennial Dr. R. Ben Alley
Endowed Lecture Series recognizes the late R. Ben Alley, DDS,
who was a leading oral and maxillofacial surgeon at the
University of Tennessee Graduate School of Medicine.
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To register or for more information, call (865) 305-9190,
or visit our web site at www.tennessee.edu/cme

Coming to Campus…

EAST TENNESSEE’S FIRST
HEART HOSPITAL
Opening Early 2010!
www.utmedicalcenter.org
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